clinical trials

News

New trial data back the use of Boehringer's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

News

Data from a new phase 3 trial of Grail's blood test for multiple cancers show improved efficacy and a lower rate of false alarms than a prior study.

News

Eli Lilly has revealed long-term follow-up data with adjuvant Verzenio in early breast cancer, including a 15.8% improvement in survival.

News

UK researchers have started a large-scale trial to test a battery of potential Parkinson's drugs to see if they can slow down disease progression.

News

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.

News

A phase 3 study suggests Pfizer's underperforming HER2 inhibitor Tukysa could play a role in first-line maintenance of HER2-positive breast cancer.